Effectiveness of PRRT for NETs in Germany: An Analysis of 450 Patients Abstract #610

Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.
Aim(s): We initiated a multi-institutional, prospective and board reviewed registry for patients treated with peptide receptor radionuclide therapy.
Materials and methods: Four hundred and fifty patients were included and followed for 17.7 months in median. Most patients were treated with Lutetium-177 (54%) or by both radionuclides. Origin of neuroendocrine neoplasms was pancreas (38%), small bowel 30%), unknown primary (19%) and lung (4%). Most neuroendocrine neoplasms were well-differentiated with a proliferation rate below 20% in 54% and were pretreated by one or more therapies in 73%.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Dr. Dieter Hörsch
Keywords: PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Keywords: PRRT, 177Lu, OPS201
#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas
Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simona Grozinsky-Glasberg
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis